Trastuzumab companion diagnostic - HER2 CISH pharmDx - Dako

Drug Profile

Trastuzumab companion diagnostic - HER2 CISH pharmDx - Dako

Alternative Names: HER2 CISH pharmDx

Latest Information Update: 22 Jun 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Dako A/S
  • Class Diagnostic agents
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer

Most Recent Events

  • 21 Jun 2012 Dako A/S has been acquired by Agilent Technologies
  • 29 Feb 2012 Launched for Breast cancer (Diagnosis) in USA (unspecified route)
  • 30 Nov 2011 Registered for Breast cancer (Diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top